Denali Therapeutics Inc.

This is the first study in people to test the safety and side effects of a new drug called DNL952 for adults with late-onset Pompe disease, a rare genetic disorder that weakens muscles. The main goal is to see how different doses are tolerated and how the drug moves through the b…